Agonist antibodies against the flk2/flt3 receptor and uses thereof
AssigneeGenentech, Inc.
InventorsBrian D. Bennett, Susan D. Broz, William Matthews, Francis C. Zeigler
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenentech, Inc.
InventorsBrian D. Bennett, Susan D. Broz, William Matthews, Francis C. Zeigler
Estimating the term…
Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.
An agonist antibody which binds to the extracellular domain of flk2/flt3 and activates the tyrosine kinase domain of flk2/flt3, wherein the antibody enhances proliferation and differentiation of myeloid and lymphoid blood cell lineages, and causes a synergistic increase in the proliferation and differentiation of primitive hematopoietic cells in combination with steel factor (SLF).
Dependencies are inferred from the claim text.